Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Melanoma Institute Australia ( Site 0152), Wollstonecraft

Lismore Base Hospital ( Site 0153), Lismore

Box Hill Hospital ( Site 0157), Box Hill

Princess Alexandra Hospital ( Site 0154), Woolloongabba

Fiona Stanley Hospital ( Site 0156), Perth

Hospital General Universitario Gregorio Maranon ( Site 0003), Madrid

Hospital Universitario Virgen de la Macarena ( Site 0004), Seville

Hospital General Universitario de Valencia ( Site 0002), Valencia

Advocate Medical Group-Park Ridge ( Site 0313), Park Ridge

Southeast Nebraska Cancer Center ( Site 0316), Lincoln

Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 0317), Dallas

Ironwood Cancer & Research Centers ( Site 0312), Chandler

John Wayne Cancer Institute ( Site 0301), Santa Monica

Inova Schar Cancer Institute ( Site 0314), Fairfax

Sunnybrook Research Institute ( Site 0654), Toronto

Princess Margaret Cancer Centre ( Site 0655), Toronto

Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0652), Montreal

McGill University Health Centre ( Site 0651), Montreal

Hospital Clinic i Provincial Barcelona ( Site 0001), Barcelona

Sahlgrenska Universitetssjukhuset ( Site 0052), Gothenburg

Skanes Universitetssjukhus ( Site 0053), Lund

Karolinska Universitetssjukhuset ( Site 0051), Solna

Norrlands Universitetssjukhus ( Site 0056), Umeå